Ramy Abdelnaby: Exploring The Timing of Antiplatelet Administration In Minor Stroke Post-Thrombolysis
Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Hui-Sheng Chen et al, published in European Heart Journal:
”Exploring the timing of antiplatelet administration in minor stroke post-thrombolysis, the EAST trial offers a comprehensive insight.
Conducted across multiple centers in China, this double-blind, randomized study evaluated the efficacy and safety of early antiplatelet treatment within 6 hours of intravenous thrombolysis in patients with mild neurological deficits.
Despite the high expectations, the trial concluded there’s no significant difference in achieving excellent functional outcomes at 90 days between the early treatment group and placebo.
This challenges existing paradigms and emphasizes the need for cautious decision-making in early antiplatelet therapy.”
Title: Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial
Authors: Hui-Sheng Chen, Yu Cui, Xiao-Qiu Li, Xin-Hong Wang, Chang-Hao Jiang, Jing Li, Zhi-Mei Yuan, Li-Wei Zhao, Nan Kong, Hai-Ning Mi, Jiang Lu, Hong Zhang, You-Jun Liu, Er-Qiang Wang, Yan Yang, Cheng-Guang Song, Yi Zhang, Shu-Yao Wang, Hong-Guo Dai, Yi Yang, Shi-Mei Geng, Rong Yin, Duo-Lao Wang, Thanh N. Nguyen
Read the Full Article on European Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 7, 2026, 16:24Kalpana Gupta Shekhawat: The Overlooked Regulator of Mast Cells – Understanding the Vagus Nerve
-
Mar 7, 2026, 16:20Purusotham Chippala: How DALYs Reveal the True Burden of Stroke
-
Mar 7, 2026, 16:13Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A
-
Mar 7, 2026, 16:05Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
-
Mar 7, 2026, 15:58Aurelio Maggio: The Mission and The Projects We Are Advancing for Rare Hematologic Diseases
-
Mar 7, 2026, 15:52Faizan Khan: The Importance of Cancer Site in Bleeding Risk Stratification for Cancer-Associated VTE
-
Mar 7, 2026, 15:50Heghine Khachatryan: How DOACs Can Cause False-Positive FVIII Inhibitor Results
-
Mar 7, 2026, 15:43Gevorg Tamamyan Joins The London Global Cancer Week Steering Group
-
Mar 7, 2026, 15:36Kenneth Monaghan: Empowering Stroke Survivors’ Self-Efficacy Through Neuroplasticity and Daily Activity